(Q33341146)

25 July 2017

title

Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience (English)

1 reference

25 July 2017

1 reference

1 reference

6

Shunji Takahashi

1 reference

25 July 2017

Katsuki Sugiyama

1

1 reference

25 July 2017

Ken Omachi

2

1 reference

25 July 2017

Keiichi Fujiwara

3

1 reference

25 July 2017

Takashi Saotome

4

1 reference

25 July 2017

Nobuyuki Mizunuma

5

1 reference

25 July 2017

Yoshinori Ito

7

1 reference

25 July 2017

Keisuke Aiba

8

1 reference

25 July 2017

Noboru Horikoshi

9

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

25 July 2017

1 reference

25 July 2017

volume

94

1 reference

25 July 2017

issue

3

1 reference

25 July 2017

page(s)

594-600

1 reference

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Effects of CPT-11 in combination with other anti-cancer agents in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10266

21 January 2018

Identifiers

DOI

10.1002/CNCR.10266

1 reference

25 July 2017

1 reference